Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib

The goal of this clinical research study is to learn if giving half of the recommended FDA approved dose of dasatinib can help to control CML as effectively as the full dose of dasatinib.


Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Estimated Enrollment: 100
Study Start Date: February 2016
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Dasatinib